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Abstract
In recent years, epidemiological studies have consistently demonstrated that the coexistence of nonalcoholic fatty liver dis-
ease (NAFLD) and type 2 diabetes mellitus (T2DM) is strongly associated with increased mortality and morbidity related 
to hepatic- and extrahepatic causes. Indeed, compared with the general population, patients with T2DM are more likely to 
be diagnosed with more severe forms of NAFLD (i.e., nonalcoholic steatohepatitis (NASH) with liver fibrosis). There is an 
ongoing debate whether NALFD is a consequence of diabetes or whether NAFLD is simply a component and manifestation 
of the metabolic syndrome, since liver fat (steatosis) and even more advanced stages of liver fibrosis can occur in the absence 
of diabetes. Nevertheless, insulin resistance is a key component of the mechanism of NAFLD development; furthermore, 
therapies that lower blood glucose concentrations also appear to be effective in the treatment of NAFLD. Here, we will dis-
cuss the pathophysiological and epidemiological associations between NAFLD and T2DM. We will also review currently 
available anti-diabetic agents with their regard to their efficacy of NAFLD/NASH treatment.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) encompasses a 
spectrum of histopathologic conditions, ranging from sim-
ple steatosis to nonalcoholic steatohepatitis (NASH), with 
or without liver fibrosis, cirrhosis and hepatocellular carci-
noma (HCC). It is defined as excess hepatic fat accumula-
tion (> 5%) in hepatocytes, assessed by either imaging or 
histology. Furthermore, secondary causes of excess liver fat, 
including significant or excess alcohol consumption (≥ 30 g/
day in men and / ≥ 20 g/day in women) must be excluded 
[1, 2].
Affecting nearly 25% of the world population, NAFLD 
can be regarded as the world's most common chronic liver 
disease [3]. Unfortunately, the burden of NALFD and its 
progressive form NASH is predicted to increase. A recently 
published modeling study, applied to China, France, Ger-
many, Italy, Japan, Spain, the UK, and the USA, has pre-
dicted a significant increase in the prevalence of NAFLD, 
with more than a doubling of cases with advanced liver 
disease and liver-related mortality in the coming years. Of 
concern, this increase in NAFLD prevalence parallels the 
predicted increase in prevalence of obesity and type 2 diabe-
tes mellitus (T2DM) [4]. Data from the United Network for 
Organ Sharing (UNOS) confirms this; in 2017, there were 
more patients with NAFLD on the liver transplant waiting 
list than there were patients with chronic viral hepatitis C 
[5].
Herein, we aim to highlight the relationship between 
NAFLD and T2DM, considering epidemiological, patho-
physiological, and clinical components. We will also discuss 
potential therapeutic strategies that may be applied to man-
aging both conditions.
Epidemiology
NAFLD represents a substantial clinical burden affecting 
25% of the world population; a recently published meta-
analysis with data obtained from 20 different countries 
reported that NAFLD prevalence is twice as high among 
those with T2DM compared with the general population. 
Among Europeans, the prevalence of NAFLD among those 
with T2DM is nearly three times higher [6]. Conversely, a 
recent meta-analysis revealed that patients with NAFLD are 
at a 2.2-fold increased risk of developing incident T2DM 
[7].
In addition to the high prevalence of NAFLD among 
those with T2DM, the presence of NAFLD appears to have 
a marked impact on clinical outcomes. In a longitudinal 
study with 150-months follow-up in patients with biopsy-
proven NAFLD, having both NAFLD and T2DM was asso-
ciated with a doubling of all-cause and liver-related mor-
tality (Hazard ratio (HR): 2.09 [95% Confidence interval 
(CI): 1.39–3.14] and 2.19 [95%CI: 1.00–4.81], respectively) 
[8]. While the estimated prevalence of NASH in the general 
population is 3–5% [3], a recent meta-analysis found that 
the global prevalence of NASH among the diabetic popu-
lation was 37.3% (95% CI 24.7–50.0%) and that a signifi-
cantly high proportion of those with T2DM and NAFLD 
had advanced NASH fibrosis (17%). The global prevalence 
of advanced fibrosis among patients with T2DM was esti-
mated as 4.8% [6]. This is of major clinical importance since 
fibrosis stage is regarded as the most important predictor 
of liver-related mortality [9]. Particular attention should be 
paid to “lean NAFLD” patients who represent up to one-fifth 
of the NAFLD population [10], who were at increased risk 
of developing T2DM [11, 12]. Furthermore, T2DM was the 
most important risk factor for NAFLD progression in this 
cohort [13].
Diabetes is also significant risk factor for the develop-
ment of hepatocellular carcinoma (HCC). One large study 
of 18 million patients revealed that diabetes is the strongest 
independent predictor of HCC or cirrhosis (HR 2.3, 95% CI 
1.9–2.78) [14], which is supported by a recent study of 354 
subjects with NASH cirrhosis that confirmed that the risk 
of HCC development is significantly increased among those 
with T2DM (HR 4.2; 95% CI 1.2–14.2) [15].
Pathophysiology and Disease Progression
Accurate predictions of the probability or rate of NAFLD 
progression cannot be made at present. Known risk factors 
for NAFLD progression include genetic factors, such as 
the Ile148Met substitution of the adiponutrin gene termed 
PNPLA3, elevated body mass index (BMI), and comor-
bid factors, particularly the presence or absence of T2DM. 
Alternative concepts regard NAFLD not as a consequence, 
but rather a cause of T2DM, since the liver releases proin-
flammatory hepatokines, which may accelerate the develop-
ment of diabetes [16].
Due to the complexities of the pathogenesis of 
NASH, the understanding of its pathogenic mechanisms 
among individual patients with NAFLD/NASH remains 
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incomplete. Fat accumulation in liver parenchymal cells 
occurs when the synthesis and supply of neutral fats 
exceed hepatic clearance. Numerous factors, includ-
ing insulin resistance, endotoxins, proinflammatory 
cytokines, oxidative stress, alterations of mitochondria, 
apoptotic processes, and genetic factors, contribute to 
NAFLD pathogenesis. Constitutional factors such as age 
and genetic predisposition, as well as clinical risk factors 
such as increased BMI, especially with visceral obesity, 
physical inactivity, increased caloric intake, and the pres-
ence of insulin resistance or type 2 diabetes, are associ-
ated with the development and/or progression of NAFLD. 
Recent studies further suggest that the composition of the 
gut microbiome and intake of specific foods such as fruc-
tose may also promote the development and/or progression 
of NAFLD [17]. Insulin resistance, especially in adipose 
tissue and skeletal muscle, is fundamental to the patho-
genesis of NAFLD. NAFLD is therefore usually regarded 
as a hepatic manifestation of the metabolic syndrome and 
diabetes. In healthy individuals, insulin inhibits hormone-
sensitive lipase in adipose tissue, inhibiting triglyceride 
hydrolysis and free fatty acid (FFA) release [18]. In those 
with NAFLD, increased visceral adipocyte mass and the 
disinhibited activity of hormone-sensitive lipase in insulin 
resistance increase triglyceride hydrolysis, which increase 
plasma levels of FFAs, especially in the portal venous 
blood. Consequently, uptake of FFA into hepatocytes is 
increased. Furthermore, skeletal muscle insulin resistance 
also indirectly increases lipid uptake into hepatocytes as a 
consequence of reduced muscle glucose uptake [19, 20]. 
Unlike adipose tissue and skeletal muscle, insulin resist-
ance is only partial in the liver of patients with NAFLD/
NASH. On the one hand, glucose regulation is dysregu-
lated in a steatotic liver (i.e., insulin resistant) [21], and 
the liver does not respond to regulatory signals; on the 
other hand, hepatic lipogenesis remains insulin sensitive 
even under insulin-resistant states, increasing lipogenesis, 
with resultant accumulation of liver triglycerides. In ani-
mal models, both insulin and glucose independently regu-
late de novo lipogenesis (DNL) via activation of the sterol- 
and carbohydrate-sensitive regulatory element binding 
proteins, SREBP-1c and ChREBP, two central genes that 
activate hepatic lipogenesis [22, 23]. Chronic hyperinsu-
linemia also decreases apolipoprotein B100 synthesis and 
thus very low-density lipoproteins (VLDL)-associated 
lipid export from liver cells. Therefore, hyperinsulinemia 
increases hepatic triglyceride synthesis with concomitant 
inhibition of triglyceride secretion as VLDL (steatosis) 
[24]. Furthermore, FFAs in the liver enhance lipid per-
oxidation generate highly reactive oxygen species (ROS) 
and stimulate the expression of proinflammatory cytokines 
such as tumor necrosis factor (TNF)-α, which enhances 
the necroinflammatory processes and liver fibrosis (steato-
hepatitis). During DNL, toxic metabolites such as diacyl-
glycerol and ceramides can also induce insulin resistance, 
thereby creating a positive feedback loop wherein insulin 
resistance stimulates hepatic DNL, and hepatic DNL in 
turn promotes insulin resistance [25].
Clinical Assessment
The complexity of pathogenic mechanisms and heterogene-
ity of NAFLD complicate accurate prediction of NAFLD 
prognosis. In general, about one-third of those with sim-
ple steatosis will progress to NASH and about one-third of 
those with NASH will develop significant liver fibrosis or 
cirrhosis.
Screening the general population for NAFLD is currently 
not recommended [2]. Even among those with NAFLD, only 
patients with an increased risk of developing complications 
need further evaluation and/or regular follow-up since only 
a minority of those with NAFLD will experience a severe 
clinical event [8]. Therefore, the evaluation and risk strati-
fication should be focused on identifying those considered 
at high risk of progression to cirrhosis and cirrhosis-asso-
ciated complications. Indeed, the European Association for 
the Study of Liver Disease (EASL) recommends a routine, 
non-invasive initial evaluation for individuals with the meta-
bolic syndrome, obesity, and T2DM [1] and the American 
Diabetes Association (ADA) guidance recommends a yearly 
assessment of liver transaminases in those with T2DM [26]. 
Screening patients using transaminases alone, however, is 
inaccurate as it will likely miss a significant proportion of 
those with significant or advanced liver fibrosis (i.e., those 
with F2 or greater fibrosis stage) since 25% of patients with 
NAFLD, and 19% of those with NASH will have normal 
transaminases [27]. At this time, the American Association 
for the Study of Liver Disease (AASLD) does not recom-
mend screening for NAFLD [2], although a recent cost-
utility analysis by investigators of NASHNET found that 
screening among those with T2DM is cost-effective [28].
As NAFLD is a component of the metabolic syndrome, 
and as such, a multisystem disorder, there is agreement that 
management of NAFLD should involve a multidiscipli-
nary approach. Such an interdisciplinary team would likely 
consist of hepatologists, diabetologists, cardiologists, and 
nutritional doctors, as well as dietitians, exercise physiolo-
gists, and psychologists [29, 30]. Indeed, studies comparing 
models of care (i.e., care provided by a multidisciplinary 
team versus single providers) in patients with heart failure 
have consistently demonstrated superior outcomes using a 
multidisciplinary approach, including a reduction of car-
diovascular risk [29, 30]. The high prevalence of NAFLD, 
however, makes it costly and impractical to provide such 
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multidisciplinary service for all patients and at all levels of 
service provision. One proposed model of care would be 
for primary care physicians and/or diabetologists to refer 
those identified at highest risk of NAFLD progression using 
established guidelines. Secondary or tertiary centers with 
greater resources should ideally manage these high-risk 
patients using a multidisciplinary approach [31, 32] (Fig. 1).
The preferred first-line diagnostic methods involve 
the use of non-invasive scoring systems based on widely 
available serum biomarkers. The Fibrosis-4 index (FIB-4) 
and NAFLD fibrosis score (NFS) are well-validated and 
recommended by several guidelines [1, 2, 33]. Due to its 
simple calculation, FIB-4 seems to be best adapted to daily 
practice [33]. The capability of those tests lies in their 
ability to exclude advanced fibrosis (i.e., excellent negative 
predictive value), rather than in diagnosing early disease, 
a desirable characteristic among those with T2DM [34, 
35]. Specifically, a FIB-4 cutoff of < 1.3 suggests a low 
risk of advanced fibrosis and a score > 2.67 suggests high 
risk of advanced fibrosis. Patients with an indeterminate 
score (i.e. ≥ 1.3 but < 2.67) or a score > 2.67 are recom-
mended to be further evaluated with a second modal-
ity (e.g., NFS, the enhanced liver fibrosis (ELF) score, 
or vibration-controlled transient elastography (VCTE)) 
[32]. For these individuals, undergoing FIB4 followed by 
VCTE appears to be the most cost-effective strategy for 
disease stratification [28, 36, 37]. This stepwise approach 
reduces the number of unnecessary liver biopsies [38, 39], 
and costs. The FibroScan-AST (FAST)™ score (alanine 
transaminase/aspartate transaminase ratio combined with 
fibroscan measurement) improves identification of those 
at the highest risk of disease progression (i.e., those with 
a NAFLD fibrosis score ≥ 4 and fibrosis stage ≥ 2) [40]. 







invasive test in 1 
year
Refer for VCTE
FIB-4<1.3 (low risk) FIB-4≥1.3 (high or indeterminate risk)
LSM<8 kPa 
(low risk)




• HCC screening 
• Life style modifications
• Cardiovascular risk 
assessment 
• Patient education
Fig. 1  Diagnostic approach in NAFLD patients with T2DM. NAFLD Nonalcoholic fatty liver disease, T2DM Type 2 diabetes mellitus, FIB-4 
Fibrosis-4 index, VCTE Vibration-controlled transient elastography, LSM Liver stiffness measurement, HCC Hepatocellular carcinoma
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(MRE) or 2D-shock wave elastography (SWE) could also 
be considered as the second modality [41, 42], but are 
costly and are currently not widely available [43].
Therapeutics
Despite the significant burden of the disease, there is no 
current approved pharmacological therapy for NAFLD 
[1, 2, 44].
Lifestyle Modification
Lifestyle modifications targeting weight loss remain 
the cornerstone of treatment, which also constitutes 
the backbone of diabetes management [44]. Indeed, a 
body weight reduction of 5% decreases liver fat content, 
whereas weight loss of 7–10% can even regress NASH 
and/or liver fibrosis [45]. In the future, digital education 
will likely assume increasing importance in the manage-
ment of NAFLD. In a recently conducted clinical trial, 
12 weeks of diet and exercise supported by digital educa-
tion reduced body weight by ~ 9% and resolved NAFLD 
in 30% of participants with NAFLD and T2DM [46]. A 
major limitation of all lifestyle modification programs is 
non-compliance and the inability to sustain weight loss 
beyond the prescribed program. Indeed, fewer than half 
of the patients undergoing lifestyle intervention programs 
achieved the targeted weight loss, and only 25% of the 
patients managed to sustain the weight loss of > 5% [47]. 
As such, there is increased efforts in developing new 
pharmacological treatment for NAFLD.
Although there is currently no approved pharmaco-
logical therapy specifically for NAFLD/NASH, several 
already approved anti-diabetic agents have shown promise 
in NAFLD/NASH. We will discuss these below.
Pharmacological Approach
While multiple NASH/anti-fibrotic agents are being evalu-
ated in phase 2 and phase 3 trials [48], several drugs already 
approved for the treatment of T2DM are beneficial for 
NAFLD/NASH. Specifically, we will summarize recent 
randomized controlled trials that evaluated (or are evaluat-
ing) anti-diabetic agents in the treatment of NAFLD/NASH 
in Tables 1 and 2.
Metformin
In diabetology, cardiovascular safety studies have led to an 
overall paradigm shift in the therapy of diabetes. Metformin 
is now listed in the current European recommendations [49] 
as the only first-line agent for diabetic patients without car-
diovascular complications. In the presence of cardiovascular 
disease, sodium-dependent glucose transporter (SGLT)-2 
inhibitors and stable glucagon-like peptide (GLP)1 ana-
logs are preferred. Most of the data on anti-diabetic drug 
therapy in NAFLD are derived from studies of metformin. 
The beneficial effect of metformin is mainly based on 
reducing the risk of HCC [50]. In a sizeable multivariable 
regression analysis [51], diabetes was associated with a 
1.35-fold increased risk of HCC compared with the con-
trol group. Analysis of associated medications showed that 
metformin, in particular, was associated with a 30% lower 
risk of HCC, as was reported in cohort analyses of other 
Table 1  Recent biopsy-proven randomized controlled trials including anti-diabetic agents
DPP Dipeptidyl peptidase, NAFLD Nonalcoholic fatty liver disease, GLP Glucagon-like peptide, NASH Nonalcoholic steatohepatitis, SGLT 
Sodium-dependent glucose transporter, PPAR Peroxisome proliferator-activated receptor
Drug group Drug name Study characteristics Outcome




fibrosis or NAFLD 
fibrosis score
GLP1 agonist Liraglutide [59] 1.8 mg/day dose of Liraglutide versus placebo
48 weeks of follow-up
NASH resolution




change in liver 
fibrosis between 
groups
SGLT-2 inhibitor – – –
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tumor entities. Sulfonylureas were neutral, whereas insulin 
therapy increased the risk of HCC 1.6-fold. Lipid-lowering 
treatment, i.e., statin use, had the most pronounced effect on 
HCC risk, with a 35% reduction. Nevertheless, metformin 
does not affect steatosis per se [50]. Indeed, a meta-analysis 
that included randomized controlled trials revealed that met-
formin did not significantly impact steatosis, ballooning, 
and fibrosis. Lobular inflammation was actually increased 
in patients taking metformin [52]. Therefore, the beneficial 
effect of metformin in NAFLD therapy remains uncertain.
Dipeptidyl Peptidase (DPP)4 Inhibitors
Since dipeptidyl peptidase (DPP)4 is the primary metabolic 
enzyme for GLP1, an enteroendocrine hormone with salu-
tary effects on insulin release, motility, and appetite [53], its 
inhibition increases the half-life  (t1/2) of GLP1 and related 
peptides in the circulation. Accumulating data suggest that 
sitagliptin has no beneficial effect on hepatic outcomes 
in NAFLD patients, although some controversial results 
showed a possible beneficial effect of sitagliptin in NASH 
improvement [54, 55]. Nonetheless, no significant improve-
ment was observed in terms of NAFLD fibrosis score and 
fibrosis stage in a biopsy-proven randomized controlled 
study [56]. Though its only advantage remains in its good 
tolerability and safety, this is insufficient justification for its 
use as a management option in NAFLD [54].
GLP1 Receptor Agonists
Stable GLP1 receptor agonist analogs significantly decrease 
body weight and food intake by reducing gastric emptying 
and possibly by affecting central satiety centers in addition 
to their hypoglycemic effects [57]. According to a recent 
meta-analysis, GLP1 receptor agonists are a new therapeu-
tic option for resolving NASH without worsening fibrosis 
[58]. In a placebo-controlled phase 2 study, liraglutide 
resolved histological NASH compared with placebo (39% 
vs. 9%, P = 0.019) though a significant change in the mean 
NAFLD activity score was not observed [59]. Semaglutide 
demonstrated similar results: patients with biopsy-proven 
NASH receiving semaglutide 0.4 mg daily resolved NASH 
at rates higher than those receiving placebo (59% vs. 17%, 
P < 0.001). Though fibrosis stage improvement was not sig-
nificantly different [60]. Exenatide reduced hepatic fat [61]. 
A combination of exenatide and dapagliflozin, a SGLT2 
inhibitor, ameliorated hepatic steatosis and fibrosis mark-
ers compared with dapagliflozin and placebo and exenatide 
alone, suggesting that combination therapies may be benefi-
cial and are worthy of further investigation [62].
SGLT2 Inhibitors
SGLT2, expressed in the renal proximal tubule, is the pri-
mary mechanism of renal capture of filtered glucose. Its 
inhibition lowers the threshold for glycosuria with resultant 
improvement in glycemic control while facilitating negative 
caloric balance [63].
In randomized clinical trials, SGLT2 inhibitors mostly 
reduced hepatic fat content [64, 65]. In line with accumulat-
ing data, SGLT2 inhibitors were proposed as valuable agents 
in the diabetic NAFLD population in order to regulate blood 
glucose and improve hepatic fat content and fibrosis [66]. 
Furthermore, beneficial effects in reducing cardiovascu-
lar risk and nephropathy progression were also proposed 
[67, 68]. A recent meta-analysis included randomized con-
trolled trials conducted in Asian populations demonstrated 
improved anthropometric measurements, liver enzymes, 
serum lipids, glycemic control, inflammatory markers, and 
serum biomarkers predicting liver fibrosis [69]. From those 
SGLT2 inhibitors, dapagliflozin and empagliflozin signifi-
cantly reduced the hepatic fat content assessed by magnetic 
resonance imaging-proton density fat fraction (MRI-PDFF) 
[70, 71]. In a biopsy-proven NASH cohort with T2DM, 
empagliflozin effectively improved liver steatosis, balloon-
ing and fibrosis, and NASH resolution in half of the patients 
in a follow-up of 6 months [72].
Peroxisome Proliferator‑Activated Receptor (PPAR) Ago‑
nists The peroxisome proliferator-activated receptor 
(PPAR)α is a nuclear receptor linked to inflammation, insu-
lin sensitization, and lipid metabolism [73]. Its agonists 
have met with some success in the treatment of metabolic 
disease. In this class of drugs, though pioglitazone acceler-
ated NASH resolution and improved advanced fibrosis [74, 
75], due to unfavorable adverse effects such as edema, bone 
fracture, cardiovascular disease development, and weight 
gain, its use in NAFLD treatment has been withdrawn [76, 
77]. Finally, a randomized controlled, double-blind trial 
reported positive effects of saroglitozar in the improvement 
of hepatic fat content diagnosed by MRI-PDFF, insulin 
resistance, alanine transaminase levels, and serum lipid pro-
files in NAFLD patients [78].
Conclusion
• This review primarily highlighted the close association 
between NAFLD and T2DM and the clinical approach 
to patients with these two conditions. The success of 
anti-diabetic drugs with NASH combined with the grow-
ing associational and pathophysiologic links between 
metabolic liver disease and the metabolic syndrome indi-
cates the bidirectional nature of the relationship between 
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these entities. Although there is no approved therapy for 
NAFLD, therapies used to treat diabetes seem to be a 
logical solution for NAFLD management. As the patho-
genesis of NAFLD becomes better understood, treatments 
aimed at the unique factors involved in NAFLD pathogen-
esis should show even better efficacy for NAFLD treat-
ment than do the currently used anti-diabetic therapies.
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